Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 1:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3193–3216 of 16,153 matching trials from the live ClinicalTrials.gov search.
Conditions
Atopic Dermatitis
Interventions
SUN13834, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 65 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
28
States / cities
Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 25 more
Conditions
HSV, Herpes Labialis
Interventions
Squaric Acid Dibutyl Ester
Drug
Lead sponsor
Squarex, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Saint Paul, Minnesota
Completed Not applicable Interventional Accepts healthy volunteers Results available

Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers

NCT06403605
Conditions
Diabetic Foot Ulcer, Ulcer Foot, Diabetic Foot
Interventions
Mirragen Advanced Wound Matrix, Fibracol
Device
Lead sponsor
ETS Wound Care, LLC
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
15
States / cities
Los Angeles, California • Pomona, California • San Francisco, California + 12 more
Conditions
Atopic Dermatitis
Interventions
RVT-501 0.2% ointment, RVT-501 0.5% ointment, Vehicle ointment
Drug · Other
Lead sponsor
Dermavant Sciences GmbH
Industry
Eligibility
12 Years to 70 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
16
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 10 more
Conditions
Onychomycosis
Interventions
MOE Antimicrobial Plasma Treatment System
Device
Lead sponsor
Moe Medical Devices
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Breast Cancer
Interventions
celecoxib 400 mg BID
Drug
Lead sponsor
University of Kansas
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Interventions
NS-229, Placebo
Drug
Lead sponsor
NS Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Denver, Colorado • Rochester, Minnesota • Cleveland, Ohio + 4 more
Conditions
Rheumatoid Arthritis
Interventions
FB704A, Placebo
Drug
Lead sponsor
Fountain Biopharma Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Breast Cancer
Interventions
Intraoperative Radiotherapy
Device
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
48 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Newport Beach, California
Conditions
Diabetic Foot
Interventions
Revita Allograft
Other
Lead sponsor
StimLabs
Industry
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Pensacola, Florida • Lake Charles, Louisiana • Springfield, Pennsylvania
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
HER-2 Positive Breast Cancer, Metastatic Breast Cancer
Interventions
IV LBH589, Oral LBH589, trastuzumab, paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Mobile, Alabama
Conditions
Diabetic Foot Ulcers
Interventions
AMNIOEXCEL, Standard of Care, Diabetic Foot Ulcers
Other
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Phoenix, Arizona • Castro Valley, California • Stockton, California + 5 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Chemical Peels and Fractional Laser on IGF-1 Levels in Skin

NCT03775031
Conditions
Skin Cancer
Interventions
Fractional Laser and Chemical Peel
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Triple Negative Breast Cancer
Interventions
TheraBionic P1
Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
22 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Central Centrifugal Cicatricial Alopecia (CCCA)
Interventions
Topical steroid class I-II, Triamcinolone Acetonide, Doxycyline, Minoxidil
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Molluscum Contagiosum
Interventions
SB206 10.3% berdazimer, vehicle gel
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
6 Months and older
Enrollment
891 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
55
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 51 more
Conditions
Breast Cancer
Interventions
Fulvestrant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
Female only
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
7
States / cities
Little Rock, Arkansas • Boston, Massachusetts • Winchester, Massachusetts + 4 more
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma, Unresectable Stage IV Cutaneous Melanoma
Interventions
Atezolizumab, Bevacizumab
Drug
Lead sponsor
F. Stephen Hodi, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Completed Phase 1Phase 2 Interventional Results available

A Study of ZN-c5 in Subjects With Breast Cancer

NCT03560531
Conditions
Breast Cancer
Interventions
ZN-c5, Palbociclib
Drug
Lead sponsor
Zeno Alpha Inc.
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Tucson, Arizona • Los Angeles, California • Bethesda, Maryland + 6 more
Conditions
Dermatitis, Atopic
Interventions
Abrocitinib 100 mg, Abrocitinib 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
3,166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
156
States / cities
Birmingham, Alabama • Anaheim, California • Encinitas, California + 101 more
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
ganetespib, paclitaxel, trastuzumab, pertuzumab
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
New York, New York
Conditions
Colorectal Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Renal Cell Carcinoma, Gastric Cancer, Pancreatic Cancer, Urothelial Cancer
Interventions
GEN1029 (HexaBody®-DR5/DR5)
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
New Haven, Connecticut • Houston, Texas
Conditions
Breast Cancer
Interventions
filgrastim, pegfilgrastim, lyso-thermosensitive liposomal doxorubicin(Thermodox), hyperthermia treatment
Biological · Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Durham, North Carolina